Company intelligence / Profile preview

VeonGen Therapeutics

Ownership: Private
Development stage: Preclinical

Overview

VeonGen’s lead program VG801 is in a first-in-human Phase 1/2 clinical trial for Stargardt disease and has received FDA Rare Pediatric Disease Designation as well as acceptance into the FDA’s Rare Disease Endpoint Advancement pilot program. The company also has a second clinical-stage program, VG901 for retinitis pigmentosa caused by CNGA1 mutations. Both programs are enabled by proprietary gene delivery platforms designed to overcome limitations of current AAV-based therapies[1][5][6].

Therapeutic areas: Ophthalmology
Modalities: Gene therapyAdeno-associated virus (AAV)-based gene therapyDual AAV gene therapy
Industry: Biotech

Drug pipeline

5 assets

VG801

4 more assets in the full pipeline.

Partnerships

Exploring partnerships with biopharmaceutical companies in other therapeutic areas beyond ophthalmology[2]. No specific partners named.

Beyond the preview

Go deeper on VeonGen Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VeonGen Therapeutics.